Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

BACKGROUND: PROMISE-1 and PROMISE-2 evaluated the preventive efficacy, tolerability, and safety of eptinezumab, a calcitonin gene-related peptide–targeted monoclonal antibody, in adults with episodic (EM) and chronic migraine (CM), finding significant reductions in migraine frequency. This post hoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Charleston, Larry, Tassorelli, Cristina, Brevig, Thomas, Hirman, Joe, Cady, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903490/
https://www.ncbi.nlm.nih.gov/pubmed/35130836
http://dx.doi.org/10.1186/s10194-022-01386-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903490/
https://www.ncbi.nlm.nih.gov/pubmed/35130836
http://dx.doi.org/10.1186/s10194-022-01386-z

Ejemplares similares